Details for Patent: 9,029,533
✉ Email this page to a colleague
Which drugs does patent 9,029,533 protect, and when does it expire?
Patent 9,029,533 protects ICLUSIG and is included in one NDA.
This patent has sixty-nine patent family members in twenty countries.
Summary for Patent: 9,029,533
| Title: | Substituted acetylenic imidazo[1,2-A]pyridazines as kinase inhibitors |
| Abstract: | This invention relates to compounds of the general formula: ##STR00001## in which the variable groups are as defined herein, and to their preparation and use. |
| Inventor(s): | Zou; Dong (Concord, MA), Huang; Wei-Sheng (Acton, MA), Thomas; R. Mathew (Sharon, MA), Romero; Jan Antoinette C. (Somerville, MA), Qi; Jiwei (West Roxbury, MA), Wang; Yihan (Newton, MA), Zhu; Xiaotian (Newton, MA), Shakespeare; William C. (Southborough, MA), Sundaramoorthi; Rajeswari (Watertown, MA), Metcalf, III; Chester A. (Needham, MA), Dalgarno; David C. (Brookline, MA), Sawyer; Tomi K. (Southborough, MA) |
| Assignee: | ARIAD Pharmaceuticals, Inc. (Cambridge, MA) |
| Application Number: | 13/801,116 |
|
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 9,029,533
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Takeda Pharms Usa | ICLUSIG | ponatinib hydrochloride | TABLET;ORAL | 203469-004 | Dec 18, 2020 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | A METHOD FOR TREATING LEUKEMIA RESULTING FROM A MUTATION IN THE BCR-ABL KINASE DOMAIN | ⤷ Try a Trial | ||||
| Takeda Pharms Usa | ICLUSIG | ponatinib hydrochloride | TABLET;ORAL | 203469-004 | Dec 18, 2020 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | A METHOD FOR TREATING PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA | ⤷ Try a Trial | ||||
| Takeda Pharms Usa | ICLUSIG | ponatinib hydrochloride | TABLET;ORAL | 203469-004 | Dec 18, 2020 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | A METHOD FOR THE TREATMENT OF LEUKEMIAS | ⤷ Try a Trial | ||||
| Takeda Pharms Usa | ICLUSIG | ponatinib hydrochloride | TABLET;ORAL | 203469-004 | Dec 18, 2020 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | A METHOD OF TREATING CHRONIC MYELOGENOUS LEUKEMIA | ⤷ Try a Trial | ||||
| Takeda Pharms Usa | ICLUSIG | ponatinib hydrochloride | TABLET;ORAL | 203469-004 | Dec 18, 2020 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | A METHOD FOR TREATING ACUTE LYMPHOBLASTIC LEUKEMIA | ⤷ Try a Trial | ||||
| Takeda Pharms Usa | ICLUSIG | ponatinib hydrochloride | TABLET;ORAL | 203469-001 | Dec 14, 2012 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | A METHOD FOR TREATING PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA | ⤷ Try a Trial | ||||
| Takeda Pharms Usa | ICLUSIG | ponatinib hydrochloride | TABLET;ORAL | 203469-001 | Dec 14, 2012 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | A METHOD FOR THE TREATMENT OF LEUKEMIAS | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,029,533
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2006331673 | ⤷ Try a Trial | |||
| Australia | 2007249924 | ⤷ Try a Trial | |||
| Australia | 2007249926 | ⤷ Try a Trial | |||
| Brazil | PI0621098 | ⤷ Try a Trial | |||
| Brazil | PI0710328 | ⤷ Try a Trial | |||
| Brazil | PI0710331 | ⤷ Try a Trial | |||
| Canada | 2634923 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
